Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00581867 · ClinicalTrials.gov registry record · Phase 1
Memory and Insulin in Early Alzheimer's Disease
A Phase 1 study of Alzheimers Disease, sponsored by Jeff Burns, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT00581867: Completed Phase 1 study of Alzheimers Disease, sponsored by Jeff Burns, MD.
NCT00581867 is a Phase 1 study of Alzheimers Disease that has completed, run by Jeff Burns, MD. The registered enrollment target is 31 participants, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00581867, a Phase 1 study of Alzheimers Disease, has completed, sponsored by Jeff Burns, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
To determine which parts of the brain are involved in insulin-related memory improvement in early Alzheimer's disease and cognitively normal older adults.
Primary Outcome
Percentage active voxels of total hippocampal volume of interest
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Insulin Aspart
Study Locations (1)
Kansas
- University of Kansas Medical Center, Hoglund Brain Imaging Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2007-10 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
What the finished NCT00581867 record still lists
NCT00581867 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Alzheimers Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00581867 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT00581867 about?
NCT00581867 is a clinical study titled "Memory and Insulin in Early Alzheimer's Disease". To determine which parts of the brain are involved in insulin-related memory improvement in early Alzheimer's disease and cognitively normal older adults.
What is the current status of trial NCT00581867?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2007-10. Estimated completion is 2012-05.
What conditions does trial NCT00581867 study?
This clinical trial studies the following conditions: Alzheimers Disease.
What interventions are being tested in trial NCT00581867?
The interventions under investigation include: Placebo (DRUG), Insulin Aspart (DRUG).
Who is sponsoring clinical trial NCT00581867?
This trial is sponsored by Jeff Burns, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00581867 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00581867's enrollment target sits among peer trials
31 117th of 147 higher than 31 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
RECRUITING · Phase 1
-
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
RECRUITING · Phase 1
-
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
RECRUITING · Phase 1
-
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
RECRUITING · Phase 1
-
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia